Return on capital (ROC) is after tax rate of return on net business assets. ROIC is unaffected by changes in interest rates or company debt and equity structure. It measures business productivity performance.
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Statement of Comprehensive Income
- Common-Size Income Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Solvency Ratios
- Common Stock Valuation Ratios
- Selected Financial Data since 2005
- Net Profit Margin since 2005
- Operating Profit Margin since 2005
- Return on Assets (ROA) since 2005
- Debt to Equity since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Return on Invested Capital (ROIC)
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net operating profit after taxes (NOPAT)1 | ||||||
| Invested capital2 | ||||||
| Performance Ratio | ||||||
| ROIC3 | ||||||
| Benchmarks | ||||||
| ROIC, Competitors4 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 NOPAT. See details »
2 Invested capital. See details »
3 2025 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × ÷ =
4 Click competitor name to see calculations.
The Return on Invested Capital (ROIC) exhibited considerable fluctuation over the five-year period. Initial values demonstrated a strong return, followed by a period of decline and subsequent recovery.
- Net Operating Profit After Taxes (NOPAT)
- NOPAT increased from US$2,239,320 thousand in 2021 to US$2,986,401 thousand in 2022, representing a substantial gain. A decrease was then observed in 2023, with NOPAT falling to US$2,639,623 thousand. A significant decline occurred in 2024, resulting in a negative value of US$-1,271,806 thousand. However, NOPAT rebounded strongly in 2025, reaching US$3,131,283 thousand, exceeding the 2022 peak.
- Invested Capital
- Invested capital increased consistently from US$9,387,100 thousand in 2021 to US$13,178,000 thousand in 2022 and further to US$13,244,000 thousand in 2023. A decrease was then noted in 2024, falling to US$9,046,000 thousand. Invested capital increased again in 2025, reaching US$10,584,200 thousand.
- Return on Invested Capital (ROIC)
- ROIC began at 23.86% in 2021 and decreased to 22.66% in 2022. A continued downward trend was observed in 2023, with ROIC falling to 19.93%. The most substantial change occurred in 2024, with ROIC becoming negative at -14.06%. A dramatic recovery was then seen in 2025, with ROIC increasing to 29.58%, surpassing the initial 2021 value and representing the highest value within the observed period.
The negative ROIC in 2024 is directly attributable to the negative NOPAT experienced that year. The substantial increase in ROIC in 2025 is driven by the combination of a return to positive and significantly increased NOPAT, alongside a moderate increase in invested capital. The fluctuations in ROIC suggest a sensitivity to changes in both profitability and capital deployment.
Decomposition of ROIC
| ROIC | = | OPM1 | × | TO2 | × | 1 – CTR3 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | = | × | × | ||||
| Dec 31, 2024 | = | × | × | ||||
| Dec 31, 2023 | = | × | × | ||||
| Dec 31, 2022 | = | × | × | ||||
| Dec 31, 2021 | = | × | × |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Operating profit margin (OPM). See calculations »
2 Turnover of capital (TO). See calculations »
3 Effective cash tax rate (CTR). See calculations »
The period under review demonstrates significant fluctuations in the components of return on invested capital. Overall, the ROIC experienced volatility, beginning at 23.86%, declining to a low of -14.06%, and recovering to 29.58% by the end of the period. This movement is directly attributable to shifts in operating profit margin, capital turnover, and the impact of the effective cash tax rate.
- Operating Profit Margin (OPM)
- The operating profit margin exhibited an initial increase from 36.91% to 46.55% before declining to 38.69%. A substantial decrease was then observed in 2024, resulting in a negative margin of -2.19%. The final year showed a recovery to 35.41%. This volatility significantly influenced the overall ROIC, as the OPM is a key driver of profitability.
- Turnover of Capital (TO)
- The turnover of capital decreased from 0.81 to 0.68 in 2022, indicating a less efficient use of capital. A slight recovery to 0.75 was noted in 2023, followed by a considerable increase to 1.22 in 2024. This trend continued with a value of 1.13 in the final year, suggesting improved capital efficiency in the latter part of the period. The increase in capital turnover partially offset the negative impact of the declining operating profit margin in 2024.
- Effective Cash Tax Rate (CTR)
- The (1 – Effective cash tax rate) began at 80.09% and decreased to 71.84% and 69.13% over the first three years. A notable shift occurred in 2024, with the value reaching 100.00%, indicating a full tax burden. The final year saw a return to a more moderate level of 73.69%. This fluctuation in the tax rate impacted the net profitability and, consequently, the ROIC.
The interplay between these three components explains the ROIC’s trajectory. The initial decline in ROIC from 2021 to 2023 was driven by a combination of decreasing operating profit margin and capital turnover. The substantial drop in ROIC in 2024 was primarily due to the negative operating profit margin and the increased tax burden. The subsequent recovery in ROIC in 2025 was a result of the improved operating profit margin and capital turnover, alongside a more favorable tax rate.
Operating Profit Margin (OPM)
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net operating profit after taxes (NOPAT)1 | ||||||
| Add: Cash operating taxes2 | ||||||
| Net operating profit before taxes (NOPBT) | ||||||
| Revenues | ||||||
| Profitability Ratio | ||||||
| OPM3 | ||||||
| Benchmarks | ||||||
| OPM, Competitors4 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2025 Calculation
OPM = 100 × NOPBT ÷ Revenues
= 100 × ÷ =
4 Click competitor name to see calculations.
The operating profit margin exhibited considerable fluctuation over the five-year period. Initial growth was followed by a significant decline and subsequent recovery.
- Operating Profit Margin (OPM) - Overall Trend
- The OPM increased from 36.91% in 2021 to a peak of 46.55% in 2022, indicating improved profitability relative to revenue. However, this was followed by a substantial decrease to 38.69% in 2023. A dramatic shift occurred in 2024, with the OPM falling to -2.19%, representing an operating loss. The OPM then rebounded strongly in 2025, reaching 35.41%.
- OPM - Key Observations
- The increase in OPM from 2021 to 2022 suggests successful cost management or pricing strategies alongside revenue growth. The decline in 2023 could be attributed to increased operating expenses or a slowdown in revenue growth. The negative OPM in 2024 is a significant concern, indicating that operating costs exceeded revenues during that year. The recovery in 2025 suggests corrective actions were taken or favorable conditions returned.
- Relationship to Net Operating Profit Before Taxes (NOPBT)
- The fluctuations in OPM directly correlate with the trends in NOPBT. The peak in OPM in 2022 aligns with the highest NOPBT value of US$4,156,831. Conversely, the negative OPM in 2024 corresponds with the negative NOPBT of US$-241,888. The return to positive NOPBT in 2025 mirrors the improvement in OPM.
- Relationship to Revenues
- Revenues consistently increased throughout the period, from US$7,574,400 in 2021 to US$12,001,300 in 2025. However, revenue growth alone was insufficient to maintain or improve profitability in 2023 and 2024, as evidenced by the declining and then negative OPM. The recovery in OPM in 2025, despite continued revenue growth, suggests improved operational efficiency or cost control.
Turnover of Capital (TO)
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Revenues | ||||||
| Invested capital1 | ||||||
| Efficiency Ratio | ||||||
| TO2 | ||||||
| Benchmarks | ||||||
| TO, Competitors3 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Invested capital. See details »
2 2025 Calculation
TO = Revenues ÷ Invested capital
= ÷ =
3 Click competitor name to see calculations.
The analysis reveals fluctuating trends in the turnover of capital over the five-year period. Revenues demonstrate consistent growth annually, while invested capital exhibits more volatility. This interplay significantly impacts the calculated turnover of capital ratio.
- Revenue Trend
- Revenues increased steadily from US$7,574,400 thousand in 2021 to US$12,001,300 thousand in 2025. This represents a substantial overall increase, indicating strong sales performance throughout the period.
- Invested Capital Trend
- Invested capital initially increased from US$9,387,100 thousand in 2021 to US$13,244,000 thousand in 2023. However, a significant decrease occurred in 2024 to US$9,046,000 thousand, followed by a moderate increase to US$10,584,200 thousand in 2025. This suggests potential shifts in capital allocation strategies or asset management practices.
- Turnover of Capital (TO) Analysis
- The turnover of capital ratio decreased from 0.81 in 2021 to 0.68 in 2022, indicating a less efficient utilization of invested capital to generate revenue. A slight recovery to 0.75 was observed in 2023. A substantial increase occurred in 2024, with the ratio reaching 1.22, suggesting improved capital utilization. The ratio then decreased slightly to 1.13 in 2025, remaining at a relatively high level compared to earlier years.
- The fluctuations in the turnover of capital ratio appear to be more closely correlated with changes in invested capital than with revenue trends. The decrease in invested capital in 2024 likely contributed significantly to the increased ratio observed in that year, despite continued revenue growth.
In summary, while revenue consistently increased, the turnover of capital experienced considerable variation, largely driven by changes in the level of invested capital. The most recent years show a higher turnover ratio, suggesting improved efficiency in capital utilization, although a slight decrease is noted in the final year of the period.
Effective Cash Tax Rate (CTR)
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net operating profit after taxes (NOPAT)1 | ||||||
| Add: Cash operating taxes2 | ||||||
| Net operating profit before taxes (NOPBT) | ||||||
| Tax Rate | ||||||
| CTR3 | ||||||
| Benchmarks | ||||||
| CTR, Competitors4 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2025 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × ÷ =
4 Click competitor name to see calculations.
The effective cash tax rate exhibited a generally increasing trend from 2021 to 2023, followed by a significant anomaly in 2024, and a subsequent decrease in 2025. This analysis details these observations and their potential implications.
- Effective Cash Tax Rate (CTR) - Trend Analysis
- The CTR increased from 19.91% in 2021 to 28.16% in 2022, representing a substantial rise of 8.25 percentage points. This increase continued into 2023, reaching 30.87%, a further increase of 2.71 percentage points. The rate then experienced a dramatic shift in 2024, with a value not reported, suggesting a potentially significant change in the company’s tax position, possibly including a tax benefit or loss. The CTR then decreased to 26.31% in 2025.
- Cash Operating Taxes and NOPBT Relationship
- Cash operating taxes increased significantly from 2021 to 2022, mirroring the increase in net operating profit before taxes (NOPBT). Both metrics remained relatively stable between 2022 and 2023. However, in 2024, NOPBT became negative, while cash operating taxes remained positive, which likely explains the missing CTR value for that year. The return to positive NOPBT in 2025 was accompanied by a corresponding increase in cash operating taxes and a CTR value that, while lower than in 2022 and 2023, was still above the 2021 level.
The fluctuations in the CTR are closely tied to the changes in NOPBT. The negative NOPBT in 2024 likely resulted in a deferred tax asset or other tax benefit, preventing a standard CTR calculation. The subsequent recovery in 2025 suggests a return to more typical tax obligations. Further investigation into the specific factors driving the 2024 NOPBT and the associated tax implications would be beneficial.